catalyst calendar
AGENUS INC · Data as of 2026-10-25
during 2026
Based on existing data, we intend during 2026 to seek Accelerated Approval in the United States and Conditional Approval in the European Union for BOT plus BAL in refractory microsatellite-stable metastatic colorectal cancer without active liver metastases.Source filing
2026
Additional updates from ongoing company and investigator sponsored trials, including Phase 2 neoadjuvant CRC trials, are expected in 2026.Source filing
during 2026
Based on existing data, we intend during 2026 to seek Accelerated Approval in the United States and Conditional Marketing Authorization in the European Union for BOT/BAL in that indication.Source filing
H2 2026
Further details from both studies are anticipated to be published in the second half of 2026.Source filing
H2 2027
Interim pathologic response data: anticipated in the second half of 2027Source filing
H2 2029
Interim analysis of EFS: anticipated in the second half of 2029Source filing
H2 2030
Final analysis of EFS: anticipated in the second half of 2030Source filing
IGCS 2026
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026Source filing
Nov 4–Nov 8
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026Source filing